MDxHealth, Cerba HealthCare Announce Collaboration
News Jul 26, 2016
MDxHealth SA and Cerba HealthCare Belgium have announced that they have signed a Collaboration Agreement to bring MDxHealth's SelectMDx(TM) for Prostate Cancer test to urology practitioners in France, Belgium and Luxembourg. Under the terms of this two-year agreement, Cerba HealthCare Belgium will offer the SelectMDx test through its laboratory network in France, Belgium and Luxembourg.
During the initial phase of the agreement, samples will be analyzed at MDxHealth's service-testing laboratory in Nijmegen, The Netherlands. The agreement will then move into a second phase, whereby the SelectMDx test will be transferred to the Molecular Biology Department of Cerba HealthCare's laboratory CRI in Zwijnaarde, Belgium.
"This exciting partnership with Cerba dramatically increases access to SelectMDx in Europe," stated Dr. Jan Groen, Chief Executive Officer, MDxHealth, "Cerba is a leading healthcare provider specializing in the delivery of advanced diagnostic assays and serving 15,000 patients per day through its 5,000 customers worldwide, who will now have access to SelectMDx."
"Compared to our current PCA3 marker, SelectMDx supports a broader segment of patients at risk of prostate cancer," added Dr. Els Decoster, Head of Molecular Biology and R&D at CRI. "We will therefore replace PCA3 with SelectMDx in our molecular test portfolio."
An FDA-approved drug has been identified that, when used with surgery, hampers metastasis in an animal model. Originally developed and approved ~65 years ago to control blood pressure, the medication resperine also prevents what are known as tumor-derived extracellular vesicles from fusing to healthy cells and sharing their cargo of disease-promoting molecules.READ MORE
SMi Presents the 2nd Annual Conference: Injectable Drug Delivery 2019
May 15 - May 16, 2019